Main Body

Index -- New York State Blood Bank Regulations Subpart 58-2, 10 NYCRR

Effective July 21, 2004

A-

B-

[Subpart 58-2: PDF file]

A

A Cells in ABO grouping 58-2.3(f), 58-2.17(a),58-2.20(d)

ABO compatibility 58-2.7

of red cells components 58-2.9(c), 58-2.7,58-2.17

ABO group 58-2.7

confirmation of donor units 58-2.17(a)

in emergency release 58-2.17(c)

label 58-2.6(d)

records of test results 58-2.11(e),58-2.12(a), 58-2.18(b)

selection of components 58-2.9(c)

ABO grouping 58-2.7

confirmation 58-2.17(a)

on allogeneic blood 58-2.3(f)

on autogeneic blood 58-2.3(f)

on infants 58-2.20(d)

on recipient blood 58-2.17(a)

required tests 58-2.3(f)

ABO incompatibility 58-2.7

crossmatching to detect 58-2.17(c) and (e)

ACD anticoagulant 58-2.6(d)(2)

accidents 58-2.3(h)

Adverse reactions

in blood donors 58-2.3(h)

in cytapheresis donors 58-2.15(c)

in plasmapheresis donors 58-2.14(e)

in transfusion recipients 58-2.16(a)

in reinfusion 58-2.27(h)

standard operating procedures for 58-2.8(b), 58-2.8(c)(7)

Age

of allogeneic donors 58-2.2(c)

of autogeneic donors 58-2.2(e)

AHF, cryoprecipitated. See Cryoprecipitate

AIDS

donor educational materials 58-2.2(d)

donor screening 58-2.2(b)

B

B Cells in ABO grouping 58-2.3(f),58-2.17(a), 58-2.20(d)

Biohazard labeling

autogeneic blood 58-2.6(d)(3)(ii)(f)

Blood bank

definition 58-2.1(a)

Blood collection 58-2.4, 58-2.6(f)

Blood collection systems

minimum requirements 58-2.6(d)

Blood components

administration 58-2.16(d)

definition 58-2.1(d)

expiration 58-2.6(f),58-2.6(h),58-2.6(j)

issuance of 58-2.6(f) through 58-2.6(l),58-2.9

labeling 58-2.6(d)

preparation of 58-2.6(f)

records of issuance 58-2.12

storage 58-2.6(d)(2), 58-2.6(f) through (j),(l) and (m)

transportation 58-2.6(g) and (m),58-2.9(a)

Blood derivatives

administration 58-2.16(d)

definition 58-2.1(e)

issuance 58-2.9

records of issuance 58-2.12

Blood donation center 58-2.13

definition 58-2.1(b)

Blood pressure

donors 58-2.2(c)

Blood products

definition 58-2.1(f)

Blood recovery 58-2.25

Blood samples. See Samples

Blood Services Activity Report 58-2.10(b),58-2.11(b)

Blood warming 58-2.16(j)

standard operating procedure 58-2.8(c),58-2.16(j)

intraoperative and postoperative 58-2.25(b)

C

Care of

blood donors 58-2.2

cytapheresis donors 58-2.15(c)

plasmapheresis donors 58-2.14(e)

Centrifuges

calibration of 58-2.7(d)

Circular of information 58-2.6(d), 58-2.6(n)

Coagulation factor concentrates

investigation of reactions 58-2.12(c)

records 58-2.12(b)

Collection of blood 58-2.4, 58-2.6, 58-2.13 (d)

Compatibility testing

blood and blood components 58-2.7(a),58-2.17(a), 58-2.17(c)

for infants 58-2.20(d)

in emergency issue 58-2.8(c), 58-2.9(c),58-2.17(c), 58-2.18(h)

in massive transfusion 58-2.17(c)

procedure 58-2.17(e)

recordkeeping 58-2.12(a)

reservation of blood 58-2.16(c)

samples for 58-2.6(e), 58-2.17(d)

Computer system

validated 58-2.17(a)

Confidential unit exclusion 58-2.2(d)

Confidentiality of records 58-2.10

Confirmation

of patient identity prior to transfusion 58-2.16(f)

of patient identity prior to reinfusion 58-2.27(g)

Consent

for allogeneic 58-2.4(a)

for autogeneic 58-2.2(a), 58-2.4(a)

for cytapheresis 58-2.15(b)

for exceptions 58-2.26(a)

for HIV testing 58-2.4(a)

for minors 58-2.2(c)

for plasmapheresis 58-2.14(c), 58-2.14(j)

for release of information 58-2.10

for transfusion outside the hospital 58-2.21(c)

Containers

blood collection 58-2.6(a)

cytapheresis 58-2.15(f)

infectious waste 58-2.21(f)

plasmapheresis 58-2.14(h), 58-2.14(i)

reinfusion 58-2.27(e)

Contamination

protection against 58-2.2(b), 58-2.6(d)(1),58-2.6(f)

visual inspection 58-2.9(d)

Coolant

suitable 58-2.9(j)

CPD anticoagulant 58-2.6(d)(2)

CPDA-1

anticoagulant 58-2.6(d)(2)

in crossmatching 58-2.6(e)

Crossmatching. See Compatibility

Cryoprecipitated AHF

expiration 58-2.6(f)

storage 58-2.6(h)

thawing 58-2.6(f), 58-2.6(l)

transfusion for FVIII replacement 58-2.6(f)

Cytapheresis

care of donor 58-2.15(c)

consent 58-2.15(b)

definition 58-2.1(i)

direction of 58-2.15(c)

donor selection 58-2.15(a), 58-2.15(c)

double red cell pheresis 58-2.15(d)

issuance of 58-2.9(b)

multiple patient-dedicated 58-2.3(e)

physician availability 58-2.15(c)

procedure 58-2.15(f)

qualifications and care of donor 58-2.15(c)

red cell, double pheresis 58-2.15(d)

red cell loss 58-2.15(d)

release of 58-2.9(b)

required tests 58-2.3

return of rbc 58-2.15

records 58-2.15(g)

supervision of 58-2.15(c)

testing 58-2.3(a), 58-2.3(d), 58-2.3(e), 58-2.9(b)

training 58-2.15(c)

volume and frequency of 58-2.15(d)

Cytomegalovirus (CMV)

use of CMV neg. products 58-2.16(a)

D

D antigen

testing donor blood for 58-2.3(f)

testing recipient blood for 58-2.17(a)

Deferral records 58-2.9(l), 58-2.11(h)

Definitions 58-2.1

Deglycerolized Red Blood Cells

expiration 58-2.6(f), 58-2.6(j)

storage 58-2.6(g)

Department

definition 58-2.1(t)

Derivatives

definition 58-2.1(e)

recordkeeping 58-2.12(b) and (c), 58-2.19

Directed donation

See Allogeneic

definition 58-2.1(r)

Director of transfusion services

responsibilities 58-2.16(a)

Disease transmission

donor notification 58-2.23

screening to prevent 58-2.2

testing to prevent 58-2.3

Disposal

of expired units 58-2.24

of untransfused units 58-2.24

of unacceptable units 58-2.3(b)

Disposition of

blood collected by phlebotomy 58-2.6(m)

recovered blood 58-2.6(m)

Disposition records

collection 58-2.11

transfusion 58-2.12, 58-2.18, 58-2.19

Donation interval

allogeneic 58-2.4(c)

autogeneic 58-2.2(e)

cytapheresis 58-2.15(d)

Donation quantity 58-2.4(b)

Donor

definition 58-2.1(c)

Donor blood

testing 58-2.3

Donor deferral 58-2.9(l), 58-2.11(h)

Donors

allogeneic. See Allogeneic blood

autogeneic. See Autogeneic blood

cytapheresis 58-2.15

deferral records 58-2.9(l), 58-2.11(h)

directed. See Allogeneic blood

educational materials for 58-2.2(d)(1)

plasmapheresis 58-2.14

qualifications of 58-2.2, 58-2.14(d)

cytapheresis 58-2.15(d)

serial plasmapheresis 58-2.14(e)

records of collection 58-2.11

selection criteria 58-2.2

Drugs

addition to blood 58-2.16(e)

cytapheresis donors 58-2.15(b),58-2.15(c)

plasmapheresis donors 58-2.14(c)

use of illegal 58-2.2(c)

E

Educational material for donors 58-2.2(d)(1)

Emergency issue of blood 58-2.3(a),58-2.8(c),58-2.9(a),58-2.9(b),58-2.9(g),58-2.17(c),58-2.18(h)

exceptions 58-2.26(b)

Equipment

for blood collection 58-2.6(b), 58-2.6(d)

for blood storage 58-2.6(g) through 58-2.6(j)

for blood irradiation 58-2.6(k)

for thawing frozen products 58-2.6(l)

records of testing 58-2.7(d)

sterility of 58-2.5

Errors

in collection 58-2.3(h)

in reinfusion 58-2.27(h)

in transfusion 58-2.16(a)

procedure manual 58-2.8(b)

Exceptions 58-2.26

Expiration date

cryoprecipitate 58-2.6(f), 58-2.6(h)

deglycerolized red cells 58-2.6(f)

fresh frozen plasma 58-2.6(f), 58-2.6(h)

frozen red cells 58-2.6(j)

labeling of 58-2.6(d)

open system 58-2.6(f)

red cells 58-2.6(g)

Expired Units

disposal of 58-2.24

storage of 58-2.24

F

FDA. See Food and Drug Administration

FFP. See Fresh Frozen Plasma

Filters

for transfusion 58-2.16(d)

Food and Drug Administration

additive solutions approved by 58-2.6(d)

compliance with 58-2.7(a)

criteria for containers, anticoagulants and reagents 58-2.6(d)

definition 58-2.1(k)

Freezers

alarms 58-2.6(h), and (j)

for cryo storage 58-2.6(h)

for frozen red cell storage 58-2.6(j)

for plasma storage 58-2.6(h)

temperature recording of 58-2.6(h), and (j)

Frequency of donation

allogeneic 58-2.4(c)

autogeneic 58-2.2(e)

cytapheresis 58-2.15(d), 58-2.15(e)

plasmapheresis 58-2.14(g)

Fresh Frozen Plasma

expiration 58-2.6(f), 58-2.6(h)

relabeling prohibited 58-2.6(h)

solvent/detergent treated plasma 58-2.1(d),(e)

storage 58-2.6(f), 58-2.6(h)

thawing 58-2.6(f), 58-2.6(l)

Frozen Red Blood Cells

expiration 58-2.6(f), 58-2.6(j)

refreezing 58-2.6(f)

storage 58-2.6(j)

thawing 58-2.6(f), (j), and (l)

G

Granulocytes

pheresis 58-2.15

Growth hormone

in donors 58-2.2(c)

H

HBsAg. See Hepatitis

HCV. See Hepatitis

Hemapheresis See also Cytapheresis 58-2.15, Plasmapheresis 58-2.14

Hematocrit

for allogeneic 58-2.2(c)

for autogeneic 58-2.2(e), 58-2.2(f)

recordkeeping 58-2.11(e)

Hemodilution. See Isovolemic hemodilution

Hemoglobin

for allogeneic 58-2.2(c)

for autogeneic 58-2.2(e), 58-2.2(f)

recordkeeping 58-2.11(e)

Heparin

as anticoagulant 58-2.6(d)(2)

Hepatitis

biohazard labeling 58-2.6(d)(3)(ii)(f)

history of in donors 58-2.2(b)

labeling 58-2.6(d)

required testing for 58-2.3(a)

test controls 58-2.3(a)

testing allogeneic donors 58-2.3(a),58-2.9(b)

testing autogeneic donors 58-2.3(a),58-2.9(b)

testing cytapheresis donors 58-2.3(a),(d),(e)

testing plasmapheresis donors 58-2.14(f)

HIV. See also Anti-HIV-1 and Anti-HIV-2

donor screening 58-2.2(b)

education on 58-2.2(d)(1)

labeling 58-2.6(d)(3)

testing results 58-2.23

testing for 58-2.3(a)

Holding facility 58-2.22

definition 58-2.1(m)

Homologous blood. See Allogeneic blood

HTLV-I. See Anti-HTLV-I

Human growth factor

donor deferral 58-2.2(c)

I

Identification

of blood components prior to transfusion 58-2.16(f)

of recipient before transfusion 58-2.16(f)

of red cells from manual pheresis prior to reinfusion 58-2.14(h)

of samples for reinfusion 58-2.27(g)

Identification number

for donor units 58-2.6(d)

Illegal injectable drug use

in donors 58-2.2(c)

Immunohematology

testing 58-2.7

Incident reporting

in collection 58-2.3(h)

in reinfusion 58-2.27(h)

in transfusion 58-2.16(a)

procedure manual 58-2.8(b)

Informed consent. See Consent

Inspection of blood products

prior to issuance 58-2.8(c), 58-2.9(d)

Institution

definition 58-2.1(o)

Intraoperative blood recovery

definition 58-2.1(j)

identification procedures 58-2.25(d)

methods 58-2.25(b)

protocol for 58-2.25(c)

recordkeeping 58-2.25(i)

storage 58-2.25(e)

transfusion of 58-2.25(a), 58-2.25(e)

untested units 58-2.25(g)

Irradiation

labeling of irradiated products 58-2.6(k)

maintenance 58-2.6(k)

protocol 58-2.6(k)

responsibility for 58-2.6(k)

Isovolemic hemodilution. See normovolemic hemodilution.

Issuance of blood, components, derivatives 58-2.6, 58-2.9

emergency 58-2.18(h)

inspection prior to transfusion 58-2.9(d)

order for 58-2.9(c)

records of 58-2.9(h), 58-2.12

records of issuance 58-2.12

reissue 58-2.9(j)

responsibility 58-2.16(a)(3)

retention of blood samples 58-2.9(i)

return of a unit of blood 58-2.9(h) and (j)

sequence of issuance 58-2.9(k)

to NYS-approved sites 58-26(m)

transportation container 58-2.9(a)

urgent requirement 58-2.9(g)

L

Labeling

ABO group 58-2.6(d)

allogeneic 58-2.6(d)

at collection 58-2.6(d)

autogeneic 58-2.6(d), 58-2.6(g)

biohazard 58-2.6(d)(3)(ii)(f)

blood or blood components 58-2.9(k)

donor identification number 58-2.6(d)

pilot blood specimen 58-2.6(d)

Rh group 58-2.6(d)

relabeling of components 58-2.6(h)

shipping container 58-2.9(a)

test results 58-2.6(d)

testing not completed 58-2.9(b)

unacceptable test results 58-2.3(a)

Laboratories

permit 58-2.6(a)

Leukapheresis See Cytapheresis 58-2.15

Licensed practical nurses 58-2.16(d)

Limited transfusion service

agreement 58-2.21(b)

availability of MD 58-2.21(e)

coverage, 24-hour-a-day 58-2.16(h)

definition of 58-2.1(l)

medical supervision 58-2.21(d)

out-of-hospital transfusions 58-2.21(c)

patient requirements 58-2.21(c)

recordkeeping 58-2.12

M

Malaria

history of in donors 58-2.2(b)

Manufacturers instructions

compliance with 58-2.7(a)

Massive transfusion 58-2.17(c)

Medical director

allogeneic donation 58-2.2(a), 58-2.6(a)

autogeneic donation 58-2.2(e), 58-2.6(a)

definition of 58-2.1(s)

direction 58-2.6(a)

Medical services

care of donor 58-2.6(a)

Medications added to blood 58-2.16(e)

Microscopes

maintenance of 58-2.7(d)

use of 58-2.7(d)

Minors

blood donation 58-2.2(c)

N

Neonatal Transfusion 58-2.20, 58-2.17(d)

Normovolemic hemodilution

definition 58-2.1(j) and (v)

identification procedures 58-2.25(d)

methods 58-2.25(b)

protocol for 58-2.25(c)

recordkeeping 58-2.25(i)

storage 58-2.25(f)

transfusion of 58-2.25(a)

untested units 58-2.25(g)

Notification

of HIV-1 and HIV-2 test results 58-2.23

O

Open system 58-2.6(f)

Ordering blood components 58-2.9(c)

Ordering blood derivatives 58-2.9(c)

Out of hospital transfusions

See Limited Transfusion Services

P

Permits

for collection of blood for transfusion 58-2.6(a)

for required testing 58-2.3(a)

Pheresis

See cytapheresis, plasmapheresis

Phlebotomy

apparatus 58-2.6(b)

records of collections 58-2.11

phlebotomy sites 58-2.6(c)

Physician

approval for autogeneic donation 58-2.2(a), 58-2.2(e)

order for transfusion 58-2.9(c)

out-of-hospital transfusion 58-2.21(d) and (e)

See also Medical Director

Plasma

for fractionation 58-2.3(c), 58-2.9(b)

solvent/detergent treated 58-2.1(d),(e)

See Fresh Frozen Plasma

Plasma derivatives

definition 58-2.1(e)

recordkeeping 58-2.19

Plasmapheresis

automated procedure 58-2.14(i)

care of donor 58-2.14(e)

consent 58-2.14(c)

definition 58-2.1(g), 58-2.1(h)

direction 58-2.14(b)

donor selection 58-2.14(a), 58-2.14(d)

laboratory testing 58-2.14(f)

manual procedure 58-2.14(h)

physician availability 58-2.14(e)

records 58-2.14(j)

required tests 58-2.3, 58-2.7, 58-2.14(f), 58-2.17

return of red cells 58-2.14(g)

serial 58-2.14(e)

standards for 58-2.14(a)

supervision of 58-2.14(e)

testing of donors 58-2.14(f)

training 58-2.14(e)

Platelets

donated by infant's mother 58-2.3(d)

storage 58-2.6(g), 58-2.6(i)

Pooling blood components 58-2.9(f)

Postoperative recovery

definition 58-2.1(j)

identification procedures 58-2.25(d)

methods 58-2.25(b)

protocol for 58-2.25(c)

recordkeeping 58-2.25(i)

storage 58-2.25(e)

transfusion of 58-2.25(a), 58-2.25(h)

untested units 58-2.25(e)

Procedures manual 58-2.8

Pulse

donors 58-2.2(c)

Q

Quality control

recordkeeping 58-2.7(c)

testing 58-2.7(a) and (b) and (c)

Quantity

of allogeneic donation 58-2.4(b)

of autogeneic donation 58-2.4(b)

Quarantine

unacceptable blood 58-2.3(a)

untested blood 58-2.3(a)

R

Reactions. See also Incident reporting

conclusions reached and signed by director 58-2.12(a)

records to be kept by blood bank 58-2.12, 58-2.18, 58-2.19

records to be kept on patient chart 58-2.18, 58-2.19

Reagents

compliance with manufacturers instructions 58-2.7(a)

for ABO grouping 58-2.3(f), 58-2.17(a)

for Rh grouping 58-2.3(f), 58-2.17(a)

for antibody detection 58-2.3(g), 58-2.17(b)

record of 58-2.7(c)

storage of 58-2.6(g), 58-2.7(b)

Recipient

blood sample retention 58-2.17(f)

blood testing 58-2.7, 58-2.17

identification of prior to transfusion 58-2.16(f)

Records

confidentiality 58-2.10

deferral 58-2.9(l), 58-2.11(h)

of coagulation factor concentrates 58-2.12(b), 58-2.12(c)

of collection 58-2.11

of cytapheresis 58-2.15(g)

of infusions 58-2.19

of issuance for transfusion 58-2.12

of plasmapheresis 58-2.14(j)

of transfusions 58-2.18

plasma derivative infusion 58-2.19

required 58-2.10

retention of 58-2.10

temperature 58-2.6(g),(h),(j), and (l)

transfusion 58-2.12

Red blood cells

deglycerolized 58-2.6(f), 58-2.6(g),58-2.6(j)

double red cell pheresis 58-2.15(d)

expiration 58-2.6

frozen 58-2.6(j)

storage of 58-2.6(g), 58-2.9(j)

Refrigerators

alarms 58-2.6(g)

for blood storage 58-2.6(g)

temperature recording 58-2.6(g)

Reinfusion 58-2.27

definition 58-2.1(u)

errors 58-2.27(h)

labeling 58-2.27(c), 58-2.27(e)

permit 58-2.27(f)

positive identification prior to reinfusion 58-2.27(g)

retention of records 58-2.27(i)

review of 58-2.27(b)

storage 58-2.27(d)

Reissue of blood 58-2.9(j)

Respiratory diseases

in donors 58-2.2(b)

Responsibility for

blood collected by phlebotomy 58-2.6(m)

blood intended for transfusion 58-2.6(m)

limited transfusion 58-2.21(b)

procedure manuals 58-2.8

recovered blood 58-2.6(m)

reinfusion 58-2.27

required tests 58-2.3(f)

testing 58-2.3(b), 58-2.7(b)

transfusion committee 58-2.16

transfusion services 58-2.16(a)

Retention

of compatibility (pre-transfusion) samples 58-2.17(f)

of donor samples issued for transfusion 58-2.9(i)

of records 58-2.10, 58-2.11(a)

of temperature records 58-2.6, 58-2.16(j)

Rh group

confirmation of 58-2.17(a)

labeling 58-2.6(d)

on allogeneic 58-2.3(f)

on autogeneic 58-2.3(f)

on neonates 58-2.20

on recipients 58-2.17(a)

required tests 58-2.3(f)

selecting blood for transfusion 58-2.9(c)

testing 58-2.7, 58-2.17

weak D 58-2.3(f)

S

Saline

See Sodium Chloride

Samples

for donor testing 58-2.6(e)

from blood issued for transfusion 58-2.9(i)

labeling pilot samples for donor blood collection 58-2.6(d)(3)(i)

pretransfusion 58-2.17(f)

storage of 58-2.6(g)

Seal

closed system 58-2.6(d)

open system 58-2.6(f)

Selection criteria

allogeneic donors 58-2.2

autogeneic donors 58-2.2

cytapheresis donors 58-2.15

plasmapheresis donors 58-2.14

Self-exclusion 58-2.2(d)

Serial plasmapheresis. See also plasmapheresis, 58-2.14.

definition 58-2.1(h)

physician oversight 58-2.14(e)

Sexually transmitted diseases

in donors 58-2.2(b)

Skin

diseases in donors 58-2.2(b)

lesions in donors 58-2.2(b)

Sodium Chloride 0.9%

in intraoperative blood recovery 58-2.25(e)

in transfusion 58-2.16(e)

Solvent/detergent treated plasma 58-2.1(d),(e)

SOP manual. See Procedures manual

Specimens

for allogeneic donor testing 58-2.6(e)

for autogeneic donor testing 58-2.6(e)

for compatibility testing 58-2.6(e), 58-2.7(a) and (b) and (d),58-2.17(f)

storage of 58-2.6(g)

Standard operating procedures. See Procedures manual

Sterile connecting device 58-2.6(f)

Sterility of equipment 58-2.5, 58-2.6(b)

Storage of blood components. See Individual components

Supervision

of cytapheresis 58-2.15(c)

of plasmapheresis 58-2.14(e)

Syphilis

biohazard labeling 58-2.6(d)(3)(ii)(f)

history of in donor 58-2.2(b)

labeling 58-2.6(d)

required laboratory test 58-2.3

test controls 58-2.3(a)

testing allogeneic donors 58-2.3(a), 58-2.9(b)

testing autogeneic donors 58-2.3(a), 58-2.9(b)

testing cytapheresis donors 58-2.3(a),(d),(e)

testing plasmapheresis donors 58-2.9(b),58-2.14(f)

T

Temperature, storage

blood in transit 58-2.6(g)

cryoprecipitate 58-2.6(h)

deglycerolized red cells 58-2.6(g)

fresh frozen plasma 58-2.6(f), 58-2.6(h)

frozen red cells 58-2.6(f), 58-2.6(j)

platelets 58-2.6(i)

records of 58-2.6

red cells 58-2.6(g), 58-2.9(j)

whole blood 58-2.6(g)

Temperature for warming blood 58-2.16(j),58-2.25(b)

Temperature of donor 58-2.2(c)

Testing

ABO group 58-2.3(f), 58-2.7(a) and (c), 58-2.17(a)

algorithms 58-2.3(b)

allogeneic blood 58-2.3, 58-2.9(b)

antibody screening 58-2.3(g), 58-2.7(a) and (c), 58-2.17(b)

autogeneic blood 58-2.3

compatibility 58-2.7(a) and (c), 58-2.17(c)

controls 58-2.3(a)

cytapheresis 58-2.3, 58-2.9(b)

immunohematology 58-2.7(c)

neonatal 58-2.20

notifying donors of HIV results 58-2.23

plasmapheresis donors 58-2.14

Rh group 58-2.3(f), 58-2.7, 58-2.17(a)

recipient blood 58-2.7, 58-2.17

records 58-2.10

reports 58-2.3(a) 58-2.3(b)

required laboratory tests 58-2.3, 58-2.7, 58-2.17

results 58-2.3(a), 58-2.3(b)

Thawing

cryoprecipitate 58-2.6(f), 58-2.6(l)

fresh frozen plasma 58-2.6(f), 58-2.6(l)

frozen red cells 58-2.6(f), 58-2.6(l)

Therapeutic procedures 58-2.2(g)

Transfusion

availability of person administering the transfusion 58-2.16(g)

committee 58-2.16

history of in donors 58-2.2(c)

identification of recipient and blood to be transfused 58-2.16(f)

limited transfusion 58-2.21

massive 58-2.17(c)

neonatal 58-2.20

qualifications of person administering transfusion 58-2.16(d)

reinfusion 58-2.27

required records 58-2.18

plasma derivatives 58-2.19

required standards for 58-2.16(a)

Transfusion committee 58-2.16(b)

composition of 58-2.16(b)

procedures 58-2.16(b), 58-2.16(i)

reservation of blood 58-2.16(c)

Transfusion complications

reporting 58-2.16(a)

records of 58-2.12(a), 58-2.12(c),58-2.18(f), 58-2.19(d)

See also Errors

Transfusion service

definition 58-2.1(n)

responsibility of director 58-2.16(a)

Transportation

authorization for 58-2.6(m)

container 58-2.9(a)

See Individual components

Tuberculosis

in donors 58-2.2(b)

U

Unacceptable test results 58-2.3(a), 58-2.9(b)

Unexpected antibodies

neonates 58-2.20

samples for 58-2.17(d)

testing allogeneic blood for 58-2.3(g)

testing recipients 58-2.17(b)

Untested blood 58-2.9(b)

V

Validated

computer system 58-2.17(a)

Venipuncture

preparation of site 58-2.6(c)

Viral hepatitis

history of 58-2.2(b)

Volume

allogeneic blood collection 58-2.4(b)

autogeneic blood collection 58-2.4(b)

within 8-week period 58-2.4(c)

W

Warming

for reinfusion 58-2.25(b)

Weight

donor 58-2.2(c)

Whole blood

for preparation of platelets 58-2.6(g)

issuance 58-2.9(d)

storage 58-2.6(g)

Index July 21, 2004

Fast Facts

History

Affiliations

Contact

Research Programs

Diagnostic & Reference Laboratories

Laboratory Quality

Scientists

News

Calendar

Employment

Index -- New York State Blood Bank Regulations Subpart 58-2, 10 NYCRR

A

B

C

D

E

F

G

H

I

L

M

N

O

P

Q

R

S

T

U

V

W